Following China's 2026 "315 Gala" - the country's annual consumer rights program known for exposing market misconduct - the once-booming exosome trend in cosmetics and medical aesthetics has rapidly cooled in China. But the real story is not the decline of a technology. It is the correction of a market driven by aggressive commercialization, exaggerated claims, and increasingly blurred compliance boundaries. As the industry moves beyond the hype cycle, exosomes in China are entering a new phase - one shaped less by marketing narratives and more by scientific validation, regulatory expectations, and long-term viability. What Regulators Are Targeting Is the Misuse of
